Cook Myosite is developing Autologous Muscle-Derived cells, which is believed to be the only novel therapy of all the available treatment options and shall account for the highest market revenue in the coming years.
LAS VEGAS, Sept. 6, 2021 /PRNewswire/ -- DelveInsight's Fecal Incontinence Market report offers detailed information on current treatment practices, emerging drugs, Fecal Incontinence market share of the individual therapies, current and forecasted Fecal Incontinence market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the key takeaways from the Fecal Incontinence Market Report:
As per DelveInsight's estimate, the total Fecal Incontinence prevalent cases were 11,345,694 in 2020 in the 7MM, which is expected to increase by 2030.
The Fecal Incontinence epidemiology analysis demonstrates a higher female FI prevalence as compared to males.
The Fecal Incontinence therapeutics market size was evaluated to be USD 1,880 million in 2020 in the 7MM.
The highest Fecal Incontinence market share is primarily dominated by the USA in the 7MM.
Key pharmaceutical and biotech companies actively engaged in the Fecal Incontinence market space include Cook MyoSite, 9 Meters Biopharma, Palette Life Sciences, among others.
The Fecal Incontinence pipeline therapies expected to get launched in the forecasted period (2021-2030) include Autologous Muscle-Derived Cells, RDD-0315, and others.
The Fecal Incontinence therapy market growth is expected to witness a surge owing to an increase in the R&D, better understanding of the etiology, increasing FI prevalence, and launch of upcoming Fecal Incontinence therapies.
Download Fecal Incontinence Market Snapshot report to understand which Fecal Incontinence drug is going to nab the maximum market share @ Fecal Incontinence Therapy Market Analysis and Forecast
Fecal Incontinence (FI) is the involuntary passage of fecal matter through the anus. Patients affected by the condition fail to control the discharge of bowel contents. It is a challenging condition with diverse etiological factors such as traumatic, neurologic, congenital, and iatrogenic.
DelveInsight's Fecal Incontinence epidemiological analysis demonstrated that the United States accounted for the highest Fecal Incontinence prevalent cases, approximately 5,587,268 cases in number, in the 7MM in 2018, which is expected to increase by 2030.
Fecal Incontinence Epidemiological Segmentation
DelveInsight's Fecal Incontinence Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:
Total Fecal Incontinence Prevalence
Gender-specific Fecal Incontinence Prevalent Cases
Risk-based Fecal Incontinence Prevalent Cases
Frequency-based Fecal Incontinence Cases
Understand how Fecal Incontinence Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Fecal Incontinence Epidemiology Market Report Summary
The Fecal Incontinence treatment options include bulking agents and biofeedback. Biofeedback is a safe, minimally invasive behavioral technique that uses auditory or visual feedback to re-educate the pelvic floor musculature. Mild incontinence can be improved by initiating simple conservative measures such as the use of Methylcellulose (Citrucel) or psyllium (Metamucil, Fiberall, and Hydrocil) can be taken daily for patients with infrequent, low volume stools.
Fecal incontinence is a debilitating condition that causes several diseases affecting the quality of life. In severe cases, it leads to patient disability and morbidity, however, its underlying pathomechanisms to date remain in dark. There is a serious need for investigatory tools that can greatly aid in the diagnosis of FI, which shall help in the timely treatment of the patient pool. Further, the available therapies do not offer a personalized approach that can address the individual needs of the patients.
Lack of awareness, embarrassment about the diseases, and the limited research available are the major unmet needs in the Fecal Incontinence market.
Know which therapy is expected to score the touchdown first @ Fecal Incontinence Therapeutic Pipeline and Market Forecast
RDD-0315: 9 Meters Biopharma
Solesta: Palette Life Sciences
Autologous MuscleDerived Cells: Cook MyoSite
Learn more about available treatments @ Fecal Incontinence Drug Pipeline Therapies
DelveInsight's Fecal Incontinence market analysis demonstrated that the United States accounted for approximately 59% of the total Fecal Incontinence market share in the 7MM in 2020. Further, the 7MM Fecal Incontinence market share is anticipated to boost in the coming next decade owing to the launch of emerging technologies, therapies such as autologous muscle progenitor cells that are potential alternative therapies for the condition. A rise in prevalence and escalation in diagnostic opportunities are some of the major drivers of the Fecal Incontinence market, whereas unreported diseases and the absence of effective treatment are some of the major barriers of the fecal incontinence market. Further, an increase in patient and practitioner awareness regarding FI will lead to better patient outcomes and improve diagnostic opportunities.
Discover more about the future market share of the therapies @ Fecal Incontinence Treatment Market Landscape and Forecast
Scope of the Fecal Incontinence Market Report
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: 9 Meters Biopharma, Palette Life Sciences, Cook MyoSite, and several others.
Key Fecal Incontinence Pipeline Therapies: RDD-0315, Solesta, Autologous MuscleDerived Cells, and several others.
Fecal Incontinence Market Segmentation: By Geography, By Fecal Incontinence Therapies
Analysis: Comparative and conjoint analysis of Fecal Incontinence emerging therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Drop by to learn more about the future market trends @ Fecal Incontinence Market Landscape and Forecast
Table of Contents
Executive Summary of Fecal Incontinence
Fecal Incontinence Market Overview at a Glance
Competitive Intelligence Analysis for Fecal Incontinence
Fecal Incontinence Disease Background and Overview
Algorithm for Diagnosis of Fecal Incontinence
Fecal Incontinence Patient Journey
Fecal Incontinence Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Fecal Incontinence Epidemiology and Patient Population
Country Wise Epidemiology of Fecal Incontinence
Fecal Incontinence Treatment
Access and Reimbursement Overview of Fecal Incontinence
Key Endpoints of Fecal Incontinence Treatment
Fecal Incontinence Emerging Therapies
Fecal Incontinence: 7 Major Market Analysis
Fecal Incontinence Market Unmet Needs
Fecal Incontinence Market Drivers
Fecal Incontinence Market Barriers
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions
DelveInsight's ''Fetal and Neonatal Monitoring Devices-Market Insights, Competitive Landscape and Market Forecast-2026'' report.
DelveInsight's 'Focal Segmental Glomerulosclerosis (FSGS)—market—2028' report.
DelveInsight's "Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's "Multiple Organ Dysfunction Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report offers actionable insights into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Dart Neuroscience, Corcept Therapeutics, Cerecin, and others.
DelveInsight's "Autoimmune pulmonary alveolar proteinosis (aPAP) - Market Insights, Epidemiology, and Market Forecast-2030" report.
DelveInsight's 'Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030' report offers actionable insights into the Narcolepsy market, epidemiology, pipeline therapies, and key companies including Cephalon Inc., Jazz Pharmaceuticals, among others.
Browse through Blog posts
Mental and addictive disorders affect a vast number of people, constituting more than 5% of all global burden of disease as measured in Disability Adjusted Life Years (DALYs).
The Bipolar depression pipeline includes Abilify, NRX-100/NRX101, Lumateperone, and Zuranolone, which are expected to grace the market in the next few years, thereby, presenting a promising Bipolar depression therapeutics market picture.
Discover more about different types of Mental health conditions and the therapeutics market landscape.
DelveInsight estimates an increasing trend of Schizophrenia prevalence in the 7MM, which was estimated to be 5,748,062 in 2020.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Discover how DelveInsight helped a Europe-based large-cap pharma company to assess its pipeline activities and make strategic decisions to outperform in the market through its Pharma and healthcare market competitive benchmarking services.
View original content:https://www.prnewswire.com/news-releases/fecal-incontinence-therapeutics-market-size-expected-to-surge-with-a-cagr-of-3-96-in-the-7mm-during-the-study-period-2018-30--delveinsight-301369748.html
SOURCE DelveInsight Business Research, LLP